Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.

@article{Chong2015CombinationOL,
  title={Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.},
  author={Elise A Chong and Tahamtan Ahmadi and Nicole A. Aqui and Jakub Svoboda and Sunita Dwivedy Nasta and Anthony R Mato and Kristy M. Walsh and Stephen J. Schuster},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2015},
  volume={21 8},
  pages={1835-42}
}
PURPOSE Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cell-mediated cytotoxicity, has the potential to synergize with rituximab, an anti-CD20 mAb. We hypothesized that the addition of lenalidomide to rituximab would improve clinical outcomes in patients with B-cell lymphomas who were previously rituximab resistant, defined as no response to or progression of lymphoma within 6 months of rituximab-based therapy. EXPERIMENTAL DESIGN We conducted a single-center, phase… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS
17 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction Lenalidomide–Rituximab for Rituximab-Resistant Lymphoma www.aacrjournals.org Clin Cancer Res

  • AG Ramsay, AJ Clear, G Kelly, R Fatah, J Matthews, F Macdougall
  • on April
  • 2015

Neoadjuvant chemoimmunotherapy modi fi es CD 4 ( þ ) CD 25 ( þ ) regulatory T cells ( treg ) in non - small cell lung cancer ( NSCLC ) patients

  • A Pircher, G Gamerith, A Amann, S Reinold, H Popper, A Gachter
  • Lung Cancer
  • 2014

Similar Papers

Loading similar papers…